Highlights Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Market Closed - Nyse Other stock markets 01:30:00 18/06/2024 am IST			5-day change	1st Jan Change
2.85 ^USD	+5.56%		+7.55%	-12.04%

07/05	Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
07/05	Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000	08/05	MT
Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M	22/03	MT
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/03	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	22/03	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference	30/23/30	CI
Armata Pharmaceuticals, Inc. Announces First Patient Dosed in the Phase 2A Portion of the Phase 1b/2a 'Disarm' Study of Ap-Sa02 in Adults with Bacteremia Due to Staphylococcus Aureus	26/23/26	CI
Armata Pharmaceuticals, Inc. Announces CFO Changes	20/23/20	CI
Armata Pharmaceuticals, Inc. Announces Executive Changes	20/23/20	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/23/14	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Armata Pharmaceuticals, Inc. Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis	06/23/06	CI
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection	22/22/22	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Armata Pharmaceuticals Says FDA Clears Application for Initial-stage Trial of Investigational Prosthetic Joint Infection Treatment	01/22/01	MT
Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections	01/22/01	CI
Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus Aureus	23/22/23	CI
Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Armata Pharmaceuticals, Inc.

Equities

ARMP

US04216R1023

Highlights

Filters